Profile: Flexibility on the move
In the early 1990s, fresh out of graduate school and armed with a chemistry PhD, Milton joined what was then Glaxo Wellcome as a medicinal chemist. 'This was back in the days when large companies like Glaxo and Pfizer were advertising for 100 organic chemists at a time,' he recalls. He soon discovered that the focus of his PhD - the chemistry of DNA - was directly applicable to the job. 'I joined the HIV programme and had the good fortune to work on several successful products during those first few years,' he says. 'My career got off to a flying start.'
Despite this initial success, Milton aspired to put his scientific background to more exciting and innovative use. He jumped at the chance to join Xenova, a small Cambridge-based biotechnology group. 'It was an opportunity to be a medium-sized fish in a small pond,' he says of his time at Xenova, where he focused on overcoming drug resistance in cancer.
From pharma to DNA sequencing
Then, by a stroke of luck, he bumped into one of the co-founders of Solexa in a Cambridge pub. Founded by two lecturers from the University of Cambridge chemistry department, Solexa was a recent spin out company with seed funding to explore a promising new DNA sequencing approach. 'I decided to step off the pharmaceutical conveyor belt,' Milton says. 'Looking back, I think that was the best move I ever made.'
Joining Solexa as head of chemistry, Milton quickly built up a multidisciplinary scientific team made up of specialists in synthetic nucleotide chemistry, fluorescence chemistry, photochemistry, enzyme engineering, molecular biology, optical physics and chip surface chemistry. Over the next 3 years, Milton's team developed the sequencing chemistry that became an integral part of the Genome Analyzer platform, which is now considered the market leader in sequencing technology and ultimately led to the sequencing of a full human genome. In 2007, Solexa was sold to Illumina for $650 million (£404 million). That was the cue for Milton's departure.
Via venture capital
To nanopore-based sequencing
From humble academic beginnings, Oxford Nanopore Technologies has thrived, expanding from 25 to 90 employees in just 2 years. Now chief scientific officer, Milton is responsible for developing the company's revolutionary nanopore-based sequencing technology, which he says has the potential to create a new generation of users. 'It will be much smaller, faster and easier to use. You won't need armies of PhD students to run it - just a well trained technician.'
Reflecting on his career to date, Milton believes that a background in chemistry affords a degree of flexibility that shouldn't be underestimated. 'In 2001 I first moved into DNA sequencing, and by 2004 my team had built what is now the standard in sequencing technology. That speaks to the fact that chemists can turn their hand to anything,' he says. Flexibility certainly characterises his future career plans. 'I'm not sure what my next career move will be. It won't be pharma, and it won't be DNA sequencing - it will be whatever interests me next,' he says. 'It's not about where you start; what matters is where you finish.'
Yfke Hager is a science writer based in Manchester, UK